Sign up for the premium plan and unlock all options
After purchasing the premium plan, you will unlock all information about drug prices and their availability.
Search
Listing 40521 - 40540 out of 566329 entries
| Country | ATC | Drug name | Drug form, strength, package | Price level | Price in € | Price in local currency | Therapeutic areas | Manufacturer / Importer |
|---|---|---|---|---|---|---|---|---|
| Australia | (L04AG06) alemtuzumab (adm: P) | Lemtrada 12 mg/1.2 mL injection, 1.2 mL vial | Solution concentrate for I.V. infusion 12 mg in 1.2 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Multiple Sclerosis | sanofi-aventisAustraliaPtyLtd |
| Australia | (L04AG06) alemtuzumab (adm: P) | Lemtrada 12 mg/1.2 mL injection, 1.2 mL vial | Solution concentrate for I.V. infusion 12 mg in 1.2 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Multiple Sclerosis | sanofi-aventisAustraliaPtyLtd |
| Australia | (L04AG06) alemtuzumab (adm: P) | Lemtrada 12 mg/1.2 mL injection, 1.2 mL vial | Solution concentrate for I.V. infusion 12 mg in 1.2 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Multiple Sclerosis | sanofi-aventisAustraliaPtyLtd |
| Australia | (L04AG06) alemtuzumab (adm: P) | Lemtrada 12 mg/1.2 mL injection, 1.2 mL vial | Solution concentrate for I.V. infusion 12 mg in 1.2 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Multiple Sclerosis | sanofi-aventisAustraliaPtyLtd |
| Australia | (L04AG08) ocrelizumab (adm: P) | Ocrevus 300 mg/10 mL injection, 10 mL vial | Solution concentrate for I.V. infusion 300 mg in 10 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Multiple Sclerosis | RocheProductsPtyLtd |
| Australia | (L04AG08) ocrelizumab (adm: P) | Ocrevus 300 mg/10 mL injection, 10 mL vial | Solution concentrate for I.V. infusion 300 mg in 10 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Multiple Sclerosis | RocheProductsPtyLtd |
| Australia | (L04AG08) ocrelizumab (adm: P) | Ocrevus 300 mg/10 mL injection, 10 mL vial | Solution concentrate for I.V. infusion 300 mg in 10 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Multiple Sclerosis | RocheProductsPtyLtd |
| Australia | (L04AG08) ocrelizumab (adm: P) | Ocrevus 300 mg/10 mL injection, 10 mL vial | Solution concentrate for I.V. infusion 300 mg in 10 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Multiple Sclerosis | RocheProductsPtyLtd |
| Australia | (L04AG08) ocrelizumab (adm: P) | Ocrevus SC 920 mg/23 mL injection, 23 mL vial | Solution for subcutaneous injection 920 mg in 23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Multiple Sclerosis | RocheProductsPtyLtd |
| Australia | (L04AG08) ocrelizumab (adm: P) | Ocrevus SC 920 mg/23 mL injection, 23 mL vial | Solution for subcutaneous injection 920 mg in 23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Multiple Sclerosis | RocheProductsPtyLtd |
| Australia | (L04AG08) ocrelizumab (adm: P) | Ocrevus SC 920 mg/23 mL injection, 23 mL vial | Solution for subcutaneous injection 920 mg in 23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Multiple Sclerosis | RocheProductsPtyLtd |
| Australia | (L04AG08) ocrelizumab (adm: P) | Ocrevus SC 920 mg/23 mL injection, 23 mL vial | Solution for subcutaneous injection 920 mg in 23 mL, 1 pcs | Ex-factory price without vat |
$0-0 |
$0-0 |
Multiple Sclerosis | RocheProductsPtyLtd |
| Australia | (L04AG11) anifrolumab (adm: P, previous atc code l04aa51. new atc 4th level l04ag valid from january 2024.) | Saphnelo 300 mg/2 mL injection, 2 mL vial | Solution concentrate for I.V. infusion 300 mg in 2 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Lupus Erythematosus, Systemic | AstraZenecaPtyLtd |
| Australia | (L04AG11) anifrolumab (adm: P, previous atc code l04aa51. new atc 4th level l04ag valid from january 2024.) | Saphnelo 300 mg/2 mL injection, 2 mL vial | Solution concentrate for I.V. infusion 300 mg in 2 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Lupus Erythematosus, Systemic | AstraZenecaPtyLtd |
| Australia | (L04AG11) anifrolumab (adm: P, previous atc code l04aa51. new atc 4th level l04ag valid from january 2024.) | Saphnelo 300 mg/2 mL injection, 2 mL vial | Solution concentrate for I.V. infusion 300 mg in 2 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Lupus Erythematosus, Systemic | AstraZenecaPtyLtd |
| Australia | (L04AG11) anifrolumab (adm: P, previous atc code l04aa51. new atc 4th level l04ag valid from january 2024.) | Saphnelo 300 mg/2 mL injection, 2 mL vial | Solution concentrate for I.V. infusion 300 mg in 2 mL, 1 pcs | Ex-factory price without vat |
$0-0 |
$0-0 |
Lupus Erythematosus, Systemic | AstraZenecaPtyLtd |
| Australia | (L04AG12) ofatumumab (adm: P) | Kesimpta 20 mg/0.4 mL injection, 0.4 mL pen device | Solution for injection 20 mg in 0.4 mL pre-filled pen, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Multiple Sclerosis, Relapsing-Remitting | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (L04AG12) ofatumumab (adm: P) | Kesimpta 20 mg/0.4 mL injection, 0.4 mL pen device | Solution for injection 20 mg in 0.4 mL pre-filled pen, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Multiple Sclerosis, Relapsing-Remitting | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (L04AG12) ofatumumab (adm: P) | Kesimpta 20 mg/0.4 mL injection, 0.4 mL pen device | Solution for injection 20 mg in 0.4 mL pre-filled pen, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Multiple Sclerosis, Relapsing-Remitting | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (L04AG12) ofatumumab (adm: P) | Kesimpta 20 mg/0.4 mL injection, 0.4 mL pen device | Solution for injection 20 mg in 0.4 mL pre-filled pen, 1 pcs | Wholesale price without vat |
$0-0 |
$0-0 |
Multiple Sclerosis, Relapsing-Remitting | NovartisPharmaceuticalsAustraliaPtyLimited |
Pages
